Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer

Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer

Pembrolizumab has been approved as first-line treatment for advanced Non-small cell lung cancer (NSCLC) patients with tumors expressing PD-L1 and in the absence of other targetable alterations. However, not all patients that meet these criteria have a durable benefit. In this monocentric study, we a...

Full description

Bibliographic Details
Main Authors: Anello Marcello Poma, Rossella Bruno, Iacopo Pietrini, Greta Alì, Giulia Pasquini, Agnese Proietti, Enrico Vasile, Sabrina Cappelli, Antonio Chella, Gabriella Fontanini
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
lung cancer
immunotherapy
tumor microenvironment
predictive biomarkers
pembrolizumab
gene expression
Online Access:https://www.mdpi.com/2072-6694/13/15/3828

Internet

https://www.mdpi.com/2072-6694/13/15/3828

Similar Items